ชีววิทยาของไวรัสตับอักเสบบี: ทบทวนวรรณกรรม
Keywords:
-Abstract
-
Downloads
Download data is not yet available.
References
1. World Health Organization. Regional action plan for viral hepatitis in South-East Asia: 2016-2021; 2017.
2. Biswas A, Panigrahi R, Pal M, Chakraborty S, Bhattacharya P, Chakrabarti S, et al. Shift in the hepatitis B virus genotype distribution in the last decade among the HBV carriers from eastern India: possible effects on the disease status and HBV epidemiology. J Med Virol. 2013;85:1340-7.
3. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20:5427-34.
4. MacCallum F. Homologous serum hepatitis. SAGE Publications; 1946.
5. Blumberg BS. Australia antigen and the biology of hepatitis B. Science. 1977;197:17-25.
6. Dane D, Cameron C, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. The lancet. 1970;295:695-8.
7. Magnius L, Mason WS, Taylor J, Kann M, Glebe D, Dény P, et al. ICTV virus taxonomy profile: Hepadnaviridae. J Gen Virol. 2020;101:571-2.
8. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118-29.
9. Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma research. 2016;2:163.
10. İnan N, Tabak F. Hepatitis B virus: Biology and life cycle; 2015.
11. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479:672-86.
12. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife. 2012;1:e00049. doi: 10.7554/eLife.00049.
13. Blanchet M, Sureau C. Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues. J Virol. 2007;81:5841-9.
14. Schulze A, Seitz S, Gripon P, Urban S. Hepatitis B Virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Zeitschrift für Gastroenterologie. 2008;46:P4_41.
15. Huang H-C, Chen C-C, Chang W-C, Tao M-H, Huang C. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol. 2012;86:9443-53.
16. Schreiner S, Nassal M. Role for the host DNA damage response in hepatitis B virus cccDNA formation-and beyond? Viruses. 2017;9:125. doi: 10.3390/v9050125.
17. Rall LB, Standring D, Laub O, Rutter W. Transcription of hepatitis B virus by RNA polymerase II. Mol Cell Biol. 1983;3:1766-73.
18. Venkatakrishnan B, Zlotnick A. The structural biology of hepatitis B virus: form and function. Annu Rev Virol. 2016;3:429-51.
19. Yuen M-F, Chen D-S, Dusheiko GM, Janssen HL, Lau DT, Locarnini SA, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:1-20.
20. Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020:104925. doi: 10.1016/j.antiviral.2020.104925.
21. Ko C, Chakraborty A, Chou W-M, Hasreiter J, Wettengel JM, Stadler D, et al. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. J Hepatol. 2018;69:1231-41.
22. Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol. 2016;65:683-91.
23. Norder H, Couroucé A-M, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol. 1992;73:3141-5.
24. Norder H, Couroucé A-M, Coursaget P, Echevarria JM, Lee S-D, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004;47:289-309.
25. Bouckaert R, Alvarado-Mora MV, Pinho JR. Evolutionary rates and HBV: issues of rate estimation with Bayesian molecular methods. Antivir Ther. 2013;18(3 Pt B):497-503.
26. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res. 2010;40:14-30.
27. Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology. 2014;57:141-50.
28. Thuy PTB, Alestig E, Liem NT, Hannoun C, Lindh M. Genotype X/C recombinant (putative genotype I) of hepatitis B virus is rare in Hanoi, Vietnam—genotypes B4 and C1 predominate. J Med Virol. 2010;82:1327-33.
29. Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol. 2009;83:10538-47.
30. Lin C-L, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5:a021436. doi: 10.1101/cshperspect.a021436.
31. Velkov S, Ott JJ, Protzer U, Michler T. The global hepatitis B virus genotype distribution approximated from available genotyping data. Genes. 2018;9:495. doi: 10.3390/genes9100495.
32. Alestig E. Geographic and genetic diversity of hepatitis B; 2011.
33. World Health Organization. Global hepatitis report 2017. Geneva: World Health Organization; 2017.
34. Previsani N, Lavanchy D. Hepatitis B. Department of communicable diseases surveillance and response. Geneva: World Health Organization; 2002.
35. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci. 2005;2:50-7.
36. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2013;31(suppl 9):J21-8.
37. Marschall T, Kretzschmar M, Mangen M-JJ, Schalm S. High impact of migration on the prevalence of chronic hepatitis B in the Netherlands. Eur J Gastroenterol Hepatol. 2008;20:1214-25.
38. MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5:a021410. doi: 10.1101/cshperspect.a021410.
39. Louisirirotchanakul S, Olinger CM, Arunkaewchaemsri P, Poovorawan Y, Kanoksinsombat C, Thongme C, et al. The distribution of hepatitis B virus genotypes in Thailand. J Med Virol. 2012;84:1541-7.
40. Posuwan N, Wanlapakorn N, Sa-Nguanmoo P, Wasitthankasem R, Vichaiwattana P, Klinfueng S, et al. The success of a universal hepatitis B immunization program as part of Thailand’s EPI after 22 years’ implementation. PLoS one. 2016;11:e0150499. do: 10.1371/journal.pone.0150499.
41. Sa‐nguanmoo P, Tangkijvanich P, Thawornsuk N, Vichaiwattana P, Prianantathavorn K, Theamboonlers A, et al. Molecular epidemiological study of hepatitis B virus among migrant workers from Cambodia, Laos, and Myanmar to Thailand. J Med Virol. 2010;82:1341-9.
42. Darpel KE, Barber J, Hope A, Wilson AJ, Gubbins S, Henstock M, et al. Using shared needles for subcutaneous inoculation can transmit bluetongue virus mechanically between ruminant hosts. Sci Rep. 2016;6:20627. Doi: 10.1038/srep20627.
43. Shikata T, Karasawa T, Abe K, Uzawa T, Suzuki H, Oda T, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis. 1977;136:571-6.
44. Bancroft WH, Snitbhan R, McNair Scott R, Tingpalapong M, Watson WT, Tanticharoenyos P, et al. Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen. J Infect Dis. 1977;135:79-85.
45. Preboth M. PHS guidelines for management of occupational exposure to HBV, HCV and HIV: management of occupational blood exposures. Am Fam Physician. 2001;64:2012-4.
46. Bond W, Favero M, Petersen N, Gravelle C, Ebert J, Maynard J. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981;1:550-1.
47. Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 2010;52:2192-205.
48. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute
hepatitis B virus infection: relation of age to the clinical expression of disease and
subsequent development of the carrier state. J Infect Dis. 1985;151:599-603.
49. Beasley RP, Shiao I-S, Stevens C, Meng H-C. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. The Lancet. 1975;306:740-1.
50. Wong F, Pai R, Van Schalkwyk J, Yoshida EM. Hepatitis B in pregnancy: a concise review of neonatal vertical transmission and antiviral prophylaxis. Ann Hepatol. 2014;13:187-95.
51. Beasley RP, George C-YL, Roan C-H, Hwang L-Y, Lan C-C, Huang F-Y, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. The Lancet. 1983;322:1099-102.
52. Nordenfelt E, Dahlquist E. HBsAg positive adopted children as a cause of intrafamilial spread of hepatitis B. Scand J Infect Dis. 1978;10:161-3.
53. Oliveira MP, Matos MA, Silva ÁM, Lopes CL, Teles SA, Matos MA, et al. Prevalence, risk behaviors, and virological characteristics of hepatitis B virus infection in a group of men who have sex with men in Brazil: results from a respondent-driven sampling survey. PLoS One. 2016;11:e0160916. doi: 10.1371/journal.pone.0160916.
54. Allain JP, Candotti D. Hepatitis B virus in transfusion medicine: still a problem? Biologicals. 2012;40:180-6.
55. World Health Organization. Screening donated blood for transfusion-transmissible infections: recommendations. Geneva: World Health Organization; 2010.
56. Evatt BL, Margolis MHS, Biswas R, Epstein MJS, Feinstone MSM, Finlayson JS, et al. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR Recomn Rep. 1991;40:1-7.
57. Saraswat S, Banerjee K, Chaudhury N, Mahant T, Khandekar P, Gupta RK, et al. Post-transfusion hepatitis type B following multiple transfusions of HBsAg-negative blood. Journal Hepatol. 1996;25:639-43.
58. Norder H, Hammas B, Larsen J, Skaug K, Magnius L. Detection of HBV DNA by PCR in serum from an HBsAg negative blood donor implicated in cases of post-transfusion hepatitis B. Chronically Evolving Viral Hepatitis: Springer; 1992. p. 116-8.
59. Chimparlee N, Oota S, Phikulsod S, Tangkijvanich P, Poovorawan Y. Hepatitis B and hepatitis C virus in Thai blood donors. Southeast Asian J Trop Med Public Health. 2011;42:609-15.
60. Kim MJ, Park Q, Min HK, Kim HO. Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010. BMC Infect Dis. 2012;12:160. doi: 10.1186/1471-2334-12-160.
61. Candotti D, Laperche S. Hepatitis B virus blood screening: need for reappraisal of blood safety measures? Front Med. 2018;5:29. doi: 10.1186/1471-2334-12-160.
62. Tabuchi A, Tanaka J, Katayama K, Mizui M, Matsukura H, Yugi H, et al. Titration of hepatitis B virus infectivity in the sera of pre‐acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol. 2008;80:2064-8.
63. Hsia CC, Purcell RH, Farshid M, Lachenbruch PA, Yu MyW. Quantification of hepatitis B virus genomes and infectivity in human serum samples. Transfusion. 2006;46:1829-35.
64. Niederhauser C, Weingand T, Candotti D, Maier A, Tinguely C, Wuillemin W, et al. Fatal outcome of a hepatitis B virus transfusion‐transmitted infection. Vox Sang. 2010;98:504-7.
65. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K, et al. Hepatitis B NAT virus‐positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang. 2005;88:77-86.
66. Hoofnagle J, Gerety R, Barker L. Hepatitis B core antigen and antibody. Dev Biol Stand. 1975;30:175-85.
67. Niederhauser C. Reducing the risk of hepatitis B virus transfusion-transmitted infection. J Blood Med. 2011;2:91-102.
68. Chunsuttiwat S, Biggs B-A, Maynard J, Thamapalo S, Laoboripat S, Bovornsin S, et al. Integration of hepatitis B vaccination into the expanded programme on immunization in Chonburi and Chiangmai provinces, Thailand. Vaccine. 1997;1:769-74.
69. Leroi C, Adam P, Khamduang W, Kawilapat S, Ngo-Giang-Huong N, Ongwandee S, et al. Prevalence of chronic hepatitis B virus infection in Thailand: a systematic review and meta-analysis. Int J Infect Dis. 2016;51:36-43.
70. Mortensen E, Kamali A, Schirmer PL, Lucero-Obusan C, Winston CA, Oda G, et al. Are current screening protocols for chronic hepatitis B virus infection adequate? Diagn Microbiol Infect Dis. 2016;85:159-67.
71. Chemin I, Guillaud O, Queyron PC, Trépo C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol. 2009;51:824-5.
72. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71:397-408.
73. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology. 2008;134:1470-81.
74. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology. 2004;127:1356-71.
75. Huang C-H, Yuan Q, Chen P-J, Zhang Y-L, Chen C-R, Zheng Q-B, et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol. 2012;57:720-9.
76. Esposito A, Sabia C, Iannone C, Nicoletti GF, Sommese L, Napoli C. Occult hepatitis infection in transfusion medicine: screening policy and assessment of current use of anti-HBc testing. Transfus Med Hemother. 2017;44:263-72.
77. Kupek E. Residual risk of hepatitis-B-infected blood donations: estimation methods and perspectives. Int Scholar Res Notices. 2013;2013. doi: 10.5402/2013/839896.
78. Candotti D, Assennato SM, Laperche S, Allain J-P, Levicnik-Stezinar S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut. 2019;68:313-21.
79. Yuen M-F, Ka-Ho Wong D, Lee C-K, Tanaka Y, Allain J-P, Fung J, et al. Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. Clin Infect Dis. 2011;52:624-32.
80. Sodhi JS, Wani N, Jeelani S, Geelani S, Akhtar F, Javid G, et al. Occult hepatitis B virus infection as a cause of posttransfusion hepatitis in patients with cancers. Indian Journal of Gastroenterology. 2013;32:291-6.
81. Seed C, Maloney R, Kiely P, Bell B, Keller A, Pink J. Blood Service Medical Services Lookback Team. Infectivity of blood components from donors with occult hepatitis B infection—Results from an Australian lookback programme. Vox Sang. 2015;108:113-22.
82. Lieshout‐Krikke RW, van Kraaij MG, Danovic F, Zaaijer HL. Rare transmission of hepatitis B virus by D utch donors with occult infection. Transfusion. 2016;56:691-8.
83. Chiewsil P. Hemovigilance: Thailand: annual report 2001-2004 and 2005-2008. J Hematol Transfus Med. 2009;19:203-9.
84. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(S5):S45-55.
85. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology. 2000;32:1117-24.
86. Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, et al. Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis. Gastroenterology. 2016;150:194-205.
87. Ahn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol. 2005;42:188-94.
88. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092-100.
89. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology. 2017;65:1451-61.
90. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104-8.
91. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology. 2003;37:1172-9.
92. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-99.
93. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98.
94. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335-52.
95. Yim HJ, Lok ASF. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43(S1):S173-81.
96. Beasley RP, Lin CC, Chien CS, Chen CJ, Hwang LY. Geographic distribution of HBsAg carriers in China. Hepatology. 1982;2:553-6.
97. Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016;36:1239-51.
98. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921-31.
99. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama. 2006;295:65-73.
100. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80-8.
101. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28:1660-5.
102. Kao JH. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol. 2008;2:553-62.
103. Zanetti A, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, et al. Hepatitis B variant in Europe. Lancet. 1988;332:1132-3.
104. Aragri M, Alteri C, Battisti A, Di Carlo D, Minichini C, Sagnelli C, et al. Multiple hepatitis B virus (HBV) quasispecies and immune-escape mutations are present in HBV surface antigen and reverse transcriptase of patients with acute hepatitis B. J Infect Dis. 2016;213:1897-905.
105. Huang YW, Lin CL, Chen PJ, Lai MY, Kao JH, Chen DS. Higher cut-off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. J Gastroenterol Hepatol. 2006;21:859-62.
106. Cholongitas E, Haidich A-B, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018;31:480-90.
107. Jackson K, Locarnini S, Gish R. Diagnostics of hepatitis B virus: standard of care and investigational. Clin Liver Dis. 2018;12:5-11.
108. Liu Y, Zeng W, Xi J, Liu H, Liao H, Yu G, et al. Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: an updated occult HBV infection definition. J Hepatol. 2019;70:557-9.
109. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(S5):S13-21.
110. St John A. The evidence to support point-of-care testing. Clin Biochem Rev. 2010;31:111-9.
111. Lange B, Cohn J, Roberts T, Camp J, Chauffour J, Gummadi N, et al. Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses. BMC Infect dis. 2017;17(suppl 1):87-106.
112. Chevaliez S, Pawlotsky JM. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. J Hepatol. 2018;69:916-26.
113. Posuwan N, Wanlapakorn N, Sintusek P, Wasitthankasem R, Poovorawan K, Vongpunsawad S, et al. Towards the elimination of viral hepatitis in Thailand by the year 2030. J Virus Erad. 2020;6:100003. doi: 10.1016/j/jve.2020.100003.
114. Greenberg DP, Vadheim CM, Wong VK, MARCY SM, Partridge S, Greene T, et al. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr Infect Dis J. 1996;15:590-6.
115. Lo K-J, Tsai Y, Lee S-D, Yeh C, Wang J, Chiang B, et al. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology. 1985;32:65-8.
116. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States; recommendations of the Advisory Committee on Immunization Practices (ACIP); Immunization of adults; Part II; 2005.
117. Likhitsup A, Lok AS. Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials. Clin Liver Dis. 2019;23:401-16.
118. Seeger C, Sohn JA. Targeting hepatitis B virus with CRISPR/Cas9. Mol Ther Nucleic Acids. 2014;3:e216. doi: 10.1038/mtna.2014.68.
119. Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016;150:194-205.
120. Bertoletti A, Tan AT. HBV as a target for CAR or TCR-T cell therapy. Curr Opin Immunol. 2020;66:35-41.
121. Nguyen MH, Wong G, Gane E, Kao J-H, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33:e00046-19. doi: 10.1128/CMR.00046-19.
2. Biswas A, Panigrahi R, Pal M, Chakraborty S, Bhattacharya P, Chakrabarti S, et al. Shift in the hepatitis B virus genotype distribution in the last decade among the HBV carriers from eastern India: possible effects on the disease status and HBV epidemiology. J Med Virol. 2013;85:1340-7.
3. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20:5427-34.
4. MacCallum F. Homologous serum hepatitis. SAGE Publications; 1946.
5. Blumberg BS. Australia antigen and the biology of hepatitis B. Science. 1977;197:17-25.
6. Dane D, Cameron C, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. The lancet. 1970;295:695-8.
7. Magnius L, Mason WS, Taylor J, Kann M, Glebe D, Dény P, et al. ICTV virus taxonomy profile: Hepadnaviridae. J Gen Virol. 2020;101:571-2.
8. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118-29.
9. Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma research. 2016;2:163.
10. İnan N, Tabak F. Hepatitis B virus: Biology and life cycle; 2015.
11. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479:672-86.
12. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife. 2012;1:e00049. doi: 10.7554/eLife.00049.
13. Blanchet M, Sureau C. Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues. J Virol. 2007;81:5841-9.
14. Schulze A, Seitz S, Gripon P, Urban S. Hepatitis B Virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Zeitschrift für Gastroenterologie. 2008;46:P4_41.
15. Huang H-C, Chen C-C, Chang W-C, Tao M-H, Huang C. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol. 2012;86:9443-53.
16. Schreiner S, Nassal M. Role for the host DNA damage response in hepatitis B virus cccDNA formation-and beyond? Viruses. 2017;9:125. doi: 10.3390/v9050125.
17. Rall LB, Standring D, Laub O, Rutter W. Transcription of hepatitis B virus by RNA polymerase II. Mol Cell Biol. 1983;3:1766-73.
18. Venkatakrishnan B, Zlotnick A. The structural biology of hepatitis B virus: form and function. Annu Rev Virol. 2016;3:429-51.
19. Yuen M-F, Chen D-S, Dusheiko GM, Janssen HL, Lau DT, Locarnini SA, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:1-20.
20. Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020:104925. doi: 10.1016/j.antiviral.2020.104925.
21. Ko C, Chakraborty A, Chou W-M, Hasreiter J, Wettengel JM, Stadler D, et al. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. J Hepatol. 2018;69:1231-41.
22. Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol. 2016;65:683-91.
23. Norder H, Couroucé A-M, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol. 1992;73:3141-5.
24. Norder H, Couroucé A-M, Coursaget P, Echevarria JM, Lee S-D, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004;47:289-309.
25. Bouckaert R, Alvarado-Mora MV, Pinho JR. Evolutionary rates and HBV: issues of rate estimation with Bayesian molecular methods. Antivir Ther. 2013;18(3 Pt B):497-503.
26. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res. 2010;40:14-30.
27. Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology. 2014;57:141-50.
28. Thuy PTB, Alestig E, Liem NT, Hannoun C, Lindh M. Genotype X/C recombinant (putative genotype I) of hepatitis B virus is rare in Hanoi, Vietnam—genotypes B4 and C1 predominate. J Med Virol. 2010;82:1327-33.
29. Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol. 2009;83:10538-47.
30. Lin C-L, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5:a021436. doi: 10.1101/cshperspect.a021436.
31. Velkov S, Ott JJ, Protzer U, Michler T. The global hepatitis B virus genotype distribution approximated from available genotyping data. Genes. 2018;9:495. doi: 10.3390/genes9100495.
32. Alestig E. Geographic and genetic diversity of hepatitis B; 2011.
33. World Health Organization. Global hepatitis report 2017. Geneva: World Health Organization; 2017.
34. Previsani N, Lavanchy D. Hepatitis B. Department of communicable diseases surveillance and response. Geneva: World Health Organization; 2002.
35. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci. 2005;2:50-7.
36. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2013;31(suppl 9):J21-8.
37. Marschall T, Kretzschmar M, Mangen M-JJ, Schalm S. High impact of migration on the prevalence of chronic hepatitis B in the Netherlands. Eur J Gastroenterol Hepatol. 2008;20:1214-25.
38. MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5:a021410. doi: 10.1101/cshperspect.a021410.
39. Louisirirotchanakul S, Olinger CM, Arunkaewchaemsri P, Poovorawan Y, Kanoksinsombat C, Thongme C, et al. The distribution of hepatitis B virus genotypes in Thailand. J Med Virol. 2012;84:1541-7.
40. Posuwan N, Wanlapakorn N, Sa-Nguanmoo P, Wasitthankasem R, Vichaiwattana P, Klinfueng S, et al. The success of a universal hepatitis B immunization program as part of Thailand’s EPI after 22 years’ implementation. PLoS one. 2016;11:e0150499. do: 10.1371/journal.pone.0150499.
41. Sa‐nguanmoo P, Tangkijvanich P, Thawornsuk N, Vichaiwattana P, Prianantathavorn K, Theamboonlers A, et al. Molecular epidemiological study of hepatitis B virus among migrant workers from Cambodia, Laos, and Myanmar to Thailand. J Med Virol. 2010;82:1341-9.
42. Darpel KE, Barber J, Hope A, Wilson AJ, Gubbins S, Henstock M, et al. Using shared needles for subcutaneous inoculation can transmit bluetongue virus mechanically between ruminant hosts. Sci Rep. 2016;6:20627. Doi: 10.1038/srep20627.
43. Shikata T, Karasawa T, Abe K, Uzawa T, Suzuki H, Oda T, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis. 1977;136:571-6.
44. Bancroft WH, Snitbhan R, McNair Scott R, Tingpalapong M, Watson WT, Tanticharoenyos P, et al. Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen. J Infect Dis. 1977;135:79-85.
45. Preboth M. PHS guidelines for management of occupational exposure to HBV, HCV and HIV: management of occupational blood exposures. Am Fam Physician. 2001;64:2012-4.
46. Bond W, Favero M, Petersen N, Gravelle C, Ebert J, Maynard J. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981;1:550-1.
47. Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 2010;52:2192-205.
48. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute
hepatitis B virus infection: relation of age to the clinical expression of disease and
subsequent development of the carrier state. J Infect Dis. 1985;151:599-603.
49. Beasley RP, Shiao I-S, Stevens C, Meng H-C. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. The Lancet. 1975;306:740-1.
50. Wong F, Pai R, Van Schalkwyk J, Yoshida EM. Hepatitis B in pregnancy: a concise review of neonatal vertical transmission and antiviral prophylaxis. Ann Hepatol. 2014;13:187-95.
51. Beasley RP, George C-YL, Roan C-H, Hwang L-Y, Lan C-C, Huang F-Y, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. The Lancet. 1983;322:1099-102.
52. Nordenfelt E, Dahlquist E. HBsAg positive adopted children as a cause of intrafamilial spread of hepatitis B. Scand J Infect Dis. 1978;10:161-3.
53. Oliveira MP, Matos MA, Silva ÁM, Lopes CL, Teles SA, Matos MA, et al. Prevalence, risk behaviors, and virological characteristics of hepatitis B virus infection in a group of men who have sex with men in Brazil: results from a respondent-driven sampling survey. PLoS One. 2016;11:e0160916. doi: 10.1371/journal.pone.0160916.
54. Allain JP, Candotti D. Hepatitis B virus in transfusion medicine: still a problem? Biologicals. 2012;40:180-6.
55. World Health Organization. Screening donated blood for transfusion-transmissible infections: recommendations. Geneva: World Health Organization; 2010.
56. Evatt BL, Margolis MHS, Biswas R, Epstein MJS, Feinstone MSM, Finlayson JS, et al. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR Recomn Rep. 1991;40:1-7.
57. Saraswat S, Banerjee K, Chaudhury N, Mahant T, Khandekar P, Gupta RK, et al. Post-transfusion hepatitis type B following multiple transfusions of HBsAg-negative blood. Journal Hepatol. 1996;25:639-43.
58. Norder H, Hammas B, Larsen J, Skaug K, Magnius L. Detection of HBV DNA by PCR in serum from an HBsAg negative blood donor implicated in cases of post-transfusion hepatitis B. Chronically Evolving Viral Hepatitis: Springer; 1992. p. 116-8.
59. Chimparlee N, Oota S, Phikulsod S, Tangkijvanich P, Poovorawan Y. Hepatitis B and hepatitis C virus in Thai blood donors. Southeast Asian J Trop Med Public Health. 2011;42:609-15.
60. Kim MJ, Park Q, Min HK, Kim HO. Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010. BMC Infect Dis. 2012;12:160. doi: 10.1186/1471-2334-12-160.
61. Candotti D, Laperche S. Hepatitis B virus blood screening: need for reappraisal of blood safety measures? Front Med. 2018;5:29. doi: 10.1186/1471-2334-12-160.
62. Tabuchi A, Tanaka J, Katayama K, Mizui M, Matsukura H, Yugi H, et al. Titration of hepatitis B virus infectivity in the sera of pre‐acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol. 2008;80:2064-8.
63. Hsia CC, Purcell RH, Farshid M, Lachenbruch PA, Yu MyW. Quantification of hepatitis B virus genomes and infectivity in human serum samples. Transfusion. 2006;46:1829-35.
64. Niederhauser C, Weingand T, Candotti D, Maier A, Tinguely C, Wuillemin W, et al. Fatal outcome of a hepatitis B virus transfusion‐transmitted infection. Vox Sang. 2010;98:504-7.
65. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K, et al. Hepatitis B NAT virus‐positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang. 2005;88:77-86.
66. Hoofnagle J, Gerety R, Barker L. Hepatitis B core antigen and antibody. Dev Biol Stand. 1975;30:175-85.
67. Niederhauser C. Reducing the risk of hepatitis B virus transfusion-transmitted infection. J Blood Med. 2011;2:91-102.
68. Chunsuttiwat S, Biggs B-A, Maynard J, Thamapalo S, Laoboripat S, Bovornsin S, et al. Integration of hepatitis B vaccination into the expanded programme on immunization in Chonburi and Chiangmai provinces, Thailand. Vaccine. 1997;1:769-74.
69. Leroi C, Adam P, Khamduang W, Kawilapat S, Ngo-Giang-Huong N, Ongwandee S, et al. Prevalence of chronic hepatitis B virus infection in Thailand: a systematic review and meta-analysis. Int J Infect Dis. 2016;51:36-43.
70. Mortensen E, Kamali A, Schirmer PL, Lucero-Obusan C, Winston CA, Oda G, et al. Are current screening protocols for chronic hepatitis B virus infection adequate? Diagn Microbiol Infect Dis. 2016;85:159-67.
71. Chemin I, Guillaud O, Queyron PC, Trépo C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol. 2009;51:824-5.
72. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71:397-408.
73. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology. 2008;134:1470-81.
74. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology. 2004;127:1356-71.
75. Huang C-H, Yuan Q, Chen P-J, Zhang Y-L, Chen C-R, Zheng Q-B, et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol. 2012;57:720-9.
76. Esposito A, Sabia C, Iannone C, Nicoletti GF, Sommese L, Napoli C. Occult hepatitis infection in transfusion medicine: screening policy and assessment of current use of anti-HBc testing. Transfus Med Hemother. 2017;44:263-72.
77. Kupek E. Residual risk of hepatitis-B-infected blood donations: estimation methods and perspectives. Int Scholar Res Notices. 2013;2013. doi: 10.5402/2013/839896.
78. Candotti D, Assennato SM, Laperche S, Allain J-P, Levicnik-Stezinar S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut. 2019;68:313-21.
79. Yuen M-F, Ka-Ho Wong D, Lee C-K, Tanaka Y, Allain J-P, Fung J, et al. Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. Clin Infect Dis. 2011;52:624-32.
80. Sodhi JS, Wani N, Jeelani S, Geelani S, Akhtar F, Javid G, et al. Occult hepatitis B virus infection as a cause of posttransfusion hepatitis in patients with cancers. Indian Journal of Gastroenterology. 2013;32:291-6.
81. Seed C, Maloney R, Kiely P, Bell B, Keller A, Pink J. Blood Service Medical Services Lookback Team. Infectivity of blood components from donors with occult hepatitis B infection—Results from an Australian lookback programme. Vox Sang. 2015;108:113-22.
82. Lieshout‐Krikke RW, van Kraaij MG, Danovic F, Zaaijer HL. Rare transmission of hepatitis B virus by D utch donors with occult infection. Transfusion. 2016;56:691-8.
83. Chiewsil P. Hemovigilance: Thailand: annual report 2001-2004 and 2005-2008. J Hematol Transfus Med. 2009;19:203-9.
84. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(S5):S45-55.
85. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology. 2000;32:1117-24.
86. Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, et al. Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis. Gastroenterology. 2016;150:194-205.
87. Ahn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol. 2005;42:188-94.
88. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092-100.
89. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology. 2017;65:1451-61.
90. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104-8.
91. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology. 2003;37:1172-9.
92. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-99.
93. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98.
94. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335-52.
95. Yim HJ, Lok ASF. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43(S1):S173-81.
96. Beasley RP, Lin CC, Chien CS, Chen CJ, Hwang LY. Geographic distribution of HBsAg carriers in China. Hepatology. 1982;2:553-6.
97. Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016;36:1239-51.
98. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921-31.
99. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama. 2006;295:65-73.
100. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80-8.
101. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28:1660-5.
102. Kao JH. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol. 2008;2:553-62.
103. Zanetti A, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, et al. Hepatitis B variant in Europe. Lancet. 1988;332:1132-3.
104. Aragri M, Alteri C, Battisti A, Di Carlo D, Minichini C, Sagnelli C, et al. Multiple hepatitis B virus (HBV) quasispecies and immune-escape mutations are present in HBV surface antigen and reverse transcriptase of patients with acute hepatitis B. J Infect Dis. 2016;213:1897-905.
105. Huang YW, Lin CL, Chen PJ, Lai MY, Kao JH, Chen DS. Higher cut-off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. J Gastroenterol Hepatol. 2006;21:859-62.
106. Cholongitas E, Haidich A-B, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018;31:480-90.
107. Jackson K, Locarnini S, Gish R. Diagnostics of hepatitis B virus: standard of care and investigational. Clin Liver Dis. 2018;12:5-11.
108. Liu Y, Zeng W, Xi J, Liu H, Liao H, Yu G, et al. Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: an updated occult HBV infection definition. J Hepatol. 2019;70:557-9.
109. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(S5):S13-21.
110. St John A. The evidence to support point-of-care testing. Clin Biochem Rev. 2010;31:111-9.
111. Lange B, Cohn J, Roberts T, Camp J, Chauffour J, Gummadi N, et al. Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses. BMC Infect dis. 2017;17(suppl 1):87-106.
112. Chevaliez S, Pawlotsky JM. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. J Hepatol. 2018;69:916-26.
113. Posuwan N, Wanlapakorn N, Sintusek P, Wasitthankasem R, Poovorawan K, Vongpunsawad S, et al. Towards the elimination of viral hepatitis in Thailand by the year 2030. J Virus Erad. 2020;6:100003. doi: 10.1016/j/jve.2020.100003.
114. Greenberg DP, Vadheim CM, Wong VK, MARCY SM, Partridge S, Greene T, et al. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr Infect Dis J. 1996;15:590-6.
115. Lo K-J, Tsai Y, Lee S-D, Yeh C, Wang J, Chiang B, et al. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology. 1985;32:65-8.
116. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States; recommendations of the Advisory Committee on Immunization Practices (ACIP); Immunization of adults; Part II; 2005.
117. Likhitsup A, Lok AS. Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials. Clin Liver Dis. 2019;23:401-16.
118. Seeger C, Sohn JA. Targeting hepatitis B virus with CRISPR/Cas9. Mol Ther Nucleic Acids. 2014;3:e216. doi: 10.1038/mtna.2014.68.
119. Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016;150:194-205.
120. Bertoletti A, Tan AT. HBV as a target for CAR or TCR-T cell therapy. Curr Opin Immunol. 2020;66:35-41.
121. Nguyen MH, Wong G, Gane E, Kao J-H, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33:e00046-19. doi: 10.1128/CMR.00046-19.
Downloads
Published
2021-06-16
Issue
Section
บทความฟื้นวิชา (Literature review)
